HCPLive Network

Antiretroviral Therapy Cuts HIV Infection in Serodiscordant Couples in China

 
MONDAY, Dec. 3 (HealthDay News) -- For uninfected partners of HIV-positive individuals in China, transmission is reduced with antiretroviral therapy for the HIV-positive individual, according to a study published online Dec. 1 in The Lancet.

Zhongwei Jia, Ph.D., from Peking University in China, and colleagues analyzed the annual rate of HIV infection in HIV-negative partners of serodiscordant couples, stratified by treatment status of the index partner. Data were collected for 38,862 serodiscordant couples in China who were added to the national epidemiology and treatment databases between 2003 and 2011.

The researchers observed a 26 percent relative reduction in the treated cohort, with rates of HIV infection of 2.6 per 100 person-years for the 14,805 couples not receiving treatment and 1.3 per 100 person-years among the 24,057 couples in the treated cohort. Across almost all demographics subgroups, reductions were seen in transmission, and these were significant in the first year (adjusted hazard ratio [aHR], 0.64). Among couples where the HIV-positive partner had been infected by blood or plasma-transfusion (aHR, 0.76) or by heterosexual intercourse (aHR, 0.69), the risk of transmission was significantly reduced in the treated cohort, but this was not so among couples where the index partner was infected by injection drug use (aHR, 0.98).

"Our results strongly support the population-wide, real-world feasibility of treating HIV-positive individuals in serodiscordant couples to prevent HIV transmission in a developing country setting, as has already been shown to be effective in a randomized clinical trial," the authors write.
 

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Further Reading
The use of first-line, generic-based antiretroviral HIV treatment in the United States could potentially save almost $1 billion in the first year of implementation, according to a study published in the Jan. 15 issue of the Annals of Internal Medicine.
Life expectancy among HIV-positive adults in the United States and Canada treated with combination antiretroviral therapy has greatly improved since 2000, with 20-year-olds now expected to live into their 70s, according to a study published online Dec. 18 in PLOS ONE.
Young people made up more than a quarter of new HIV infections in the United States in 2010, but only a relatively small proportion of youths have been tested, and more than half who have HIV are unaware that they have the virus, according to research published in the Nov. 27 early-release issue of the U.S. Centers for Disease Control and Prevention's Morbidity & Mortality Weekly Report.
A new vaccination strategy is effective against genital herpes and possibly other sexually transmitted infections, according to an experimental study published online Oct. 17 in Nature.
Study finds that nearly 20% of adolescents infected with HIV since birth did not know their HIV status when they first became sexually active.
An intravaginal ring can steadily release tenofovir over 90 days, similar to or better than a clinically tested gel, according to an experimental study presented at the annual meeting of the American Association of Pharmaceutical Scientists, held from Oct. 14 to 18 in Chicago.
Study results presented at the 2013 United States Conference on AIDS show that both combo drugs have a similar efficacy profile in ART-naïve patients, but patients treated with Complera reported fewer and less severe side effects.
More Reading